In addition, our work further validates EZH2 as a therapeutic target in MLL-rearranged leukemias and, from the use of another mouse model and a number of different AML patient samples, extends this therapeutic potential more generally across other AML genotypes. This evidence concerns the gene KMT2A and acute myeloid leukemia.